Skip to content

Annotated sources — patient-voice layer

All PubMed records retrieved live on 2026-09-02 via E-utilities; all web pages retrieved by HTTP request on 2026-09-02 with status code and page title recorded (see organizations.md).

Peer-reviewed qualitative and patient-reported studies

Source Design and sample Scope What it contributes Themes
Hurtado MM, et al. 'I have anxiety, but I have values and preferences': Experiences of users with generalized anxiety disorder: A qualitative study. Int J Ment Health Nurs. 2020;29:521-530. PMID 31908140 Focus groups with people diagnosed with GAD; content analysis; five thematic categories GAD-specific The most directly relevant values-and-preferences study located. Physical symptoms dominate presentation; social support perceived as low; occupational interference prominent; patient involvement in decisions "scarce" and medication always offered first T1, T2, T4, T7
Toledo-Chávarri A, et al. Framing the process in the implementation of care for people with generalized anxiety disorder in primary care: a qualitative evidence synthesis. BMC Fam Pract. 2020;21:237. PMID 33218311 Qualitative evidence synthesis of implementation and care processes GAD-specific care Extends patient voice beyond a single focus-group study and locates experience within primary-care implementation T1, T2, T7
Inness BE, et al. Problematic behaviours associated with generalized anxiety disorder during pregnancy and the postpartum period: A thematic analysis. Psychol Psychother. 2022;95:921-938. PMID 35716017 Thematic analysis Perinatal GAD GAD-specific qualitative evidence in a defined life stage T6
Marcus M, et al. Client experiences of motivational interviewing for generalized anxiety disorder: a qualitative analysis. Psychother Res. 2011;21:447-461. PMID 21644188 Qualitative analysis of client treatment experience GAD-specific treatment process Shows that qualitative GAD work predates Hurtado and includes psychotherapy process T2, T7
Aucoin M, et al. Participant Experience in a Study of Dietary Counselling plus Omega-3 Supplementation for the Treatment of Generalized Anxiety Disorder among Women: A Focus Group Study. Neuropsychobiology. 2026;85:141-155. PMID 41587136 Focus-group study nested in a treatment study Women with GAD; treatment process Adds recent participant-experience evidence, while its intervention-specific sample limits generalisability T2, T4
Parker D, et al. Patients' experiences of seeking help for emotional concerns in primary care: doctor as drug, detective and collaborator. BMC Fam Pract. 2020;21:35. PMID 32059636 18 adults, 4 focus groups, thematic analysis Emotional concerns in primary care (not GAD-specific) Three roles patients want from a GP: therapeutic relationship with continuity; detective/validator who explores life circumstances; collaborator. Patients valued not relying solely on medication T1, T2, T7
Kalpakidou AK, et al. Barriers to recruitment when conducting a commissioned randomised controlled trial of medication versus psychological therapy for generalised anxiety disorder. Trials. 2019;20:284. PMID 31126337 (ISRCTN14845583) Analysis of recruitment failure in a discontinued NIHR-funded GAD RCT across four English IAPT sites GAD-specific Three-quarters of identified patients declined, most because they did not want random assignment to medication; only ~12% of potentially eligible patients were identified by practitioners; only 5% of those with GAD-7 ≥10 at service entry would have been eligible T2
Fisher K, et al. Men's anxiety: A systematic review. J Affect Disord. 2021;295:688-702. PMID 34517242 25 studies (19 quantitative, 5 qualitative, 1 mixed) from 8,333 citations Anxiety disorders in men (pooled) Self-reliance over formal help-seeking; problem-based coping; psychosomatic symptom profiles persisting over time; masculinity norms operate in both directions; help-seeking itself generates social and self-stigma T3
Lui JC, et al. Barriers and facilitators to help-seeking for common mental disorders among university students: a systematic review. J Am Coll Health. 2024;72:2605-2613. PMID 36084266 10 studies, 1990–2021 Depression and anxiety in students (pooled) Barriers: self-reliance, stigma, poor mental health literacy. Facilitators: mental health literacy, social encouragement T3
Woodgate RL, et al. The experience of the self in Canadian youth living with anxiety: A qualitative study. PLoS One. 2020;15:e0228193. PMID 32004336 58 Canadian youth aged 10–22 (44 female, 14 male); hermeneutic phenomenology with interviews, ecomaps and photovoice Anxiety in youth (pooled) Fractured sense of self; self-scrutiny without self-compassion; responsibility for others at the cost of self; value of shared lived-experience space without fear of stigmatisation T4
Oh S, et al. Exploring women's experiences of identifying, negotiating and managing perinatal anxiety: a qualitative study. BMJ Open. 2020;10:e040731. PMID 33380483 17 women aged 25–42 with self-reported perinatal anxiety; semi-structured interviews; thematic analysis Perinatal anxiety Barriers to disclosure; help-seeking; establishing support networks — all "pervaded by stigma"; call for parity with perinatal depression T3, T6
Ali E. Women's experiences with postpartum anxiety disorders: a narrative literature review. Int J Womens Health. 2018;10:237-249. PMID 29881312 14 studies from 44 articles Postpartum GAD, panic, OCD, PTSD Loss, frustration and guilt with physical tension across studies; most women had more than one anxiety disorder plus postpartum depression; evidence on clinical and subclinical symptom outcomes "lacking" T6
Saeed Q, et al. Lived experiences of mothers with postnatal anxiety: a qualitative phenomenology study from Pakistan. BMJ Open. 2024;14:e078203. PMID 38772885 10 women with GAD-7 ≥10 within 12 months of live birth; two community settings in Karachi Postnatal anxiety, LMIC Perceived drivers: navigating domestic responsibilities and sociocultural norms of motherhood; financial constraints. Distinct support needs. First such evidence from Pakistan T6
Mahmood R, et al. The lived experience of withdrawal from SSRI antidepressants: A qualitative interview study. Health Expect. 2024;27:e13966. PMID 39102706 20 community participants who had attempted SSRI withdrawal in the previous year; inductive reflexive thematic analysis; 8 PPI contributors informed design Antidepressant withdrawal (not GAD-specific) Release from emotional blunting and cognitive suppression; impact on relationships; exercise as coping; importance of GP/family support and others' mental-health literacy; need for gradual, flexible, well-timed tapering T5
Boland M, et al. 'I Wish It Were More Often Told to People Before They Are Prescribed These Medications How Hard It Is to Get Off Them': A Qualitative Descriptive Analysis of Free-Text Responses to a Survey on Reducing and Stopping Psychiatric Medication. Health Expect. 2025;28:e70384. PMID 40790920 483 in-scope free-text responses of 705 received; three stakeholder groups; template analysis; part of a James Lind Alliance Priority Setting Partnership Psychiatric medication discontinuation (not GAD-specific) Six themes: experiences, challenges, strategies, outcomes, emotional context, areas for improvement. Emphasises uncertainty about optimal tapering and the value of psychosocial support T5

Quantitative sources used to triangulate patient-reported themes

Source Contribution
Romera I, et al. J Affect Disord. 2010;127:160-8. PMID 20541811 Painful physical symptoms in 59.0% of GAD vs 28.3% of controls, 78.0% with comorbid MDD — the quantitative counterpart of theme T1
Wittchen HU, et al. J Clin Psychiatry. 2002;63 Suppl 8:24-34. PMID 12044105 Emotional problems recognised in 72.5% of pure-GAD patients but correct diagnosis in only 34.4%
Dennis CL, et al. Br J Psychiatry. 2017;210:315-323. PMID 28302701 Perinatal GAD prevalence 4.1% antenatal, 5.7% postnatal
Nelson HD, et al. Ann Intern Med. 2020;173:29-41. PMID 32510989 No treatment trials in pregnant or postpartum women identified
Henssler J, et al. Lancet Psychiatry. 2024;11:526-535. PMID 38851198 Discontinuation symptoms in 31% vs 17% placebo
Kalfas M, et al. JAMA Psychiatry. 2025;82:896-904. PMID 40632531 DESS week-1 SMD 0.31, ≈1 extra symptom; mood worsening not associated with discontinuation
Roy-Byrne P, et al. JAMA. 2010;303:1921-8. PMID 20483968 Collaborative care NNT 5.27 for response — the service model matching what patients describe wanting
Bandelow B, Michaelis S. Dialogues Clin Neurosci. 2015;17:327-35. PMID 26487813 The lifetime figure (up to 33.7%) that CAMH's public page cites to patients

Organisation and portal sources

All retrieved 2026-09-02; full table with HTTP statuses in organizations.md.

  • World Health Organization — "Anxiety disorders" fact sheet, dated 8 September 2025. https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders (accessed 2026-09-02). 359 million people in 2021; 4.4% of the global population; most common of all mental disorders; more women than men; onset often in childhood or adolescence; only ~1 in 4 in need (27.6%) receive treatment.
  • NIMH — "Generalized Anxiety Disorder: What You Need to Know". https://www.nimh.nih.gov/health/publications/generalized-anxiety-disorder-gad (accessed 2026-09-02). The only GAD-dedicated government fact sheet located; available in Spanish.
  • Anxiety UK — "Home". https://www.anxietyuk.org.uk/ (accessed 2026-09-02). User-led since 1970; lived-experience advisors; therapy from £20/session; "Stories of Hope" testimony section.
  • No Panic — "Home". https://nopanic.org.uk/ (accessed 2026-09-02). Helpline 10:00–22:00, 365 days/year; CBT-focused mentoring; carer and youth resources.
  • SANE Australia — "SANE Australia". https://www.sane.org/ (accessed 2026-09-02). Free, anonymous, professionally moderated 24/7 forums.
  • Beyond Blue — "Understand Anxiety disorders". https://www.beyondblue.org.au/mental-health/anxiety (accessed 2026-09-02). States 1 in 4 people in Australia affected.
  • CAMH — "Anxiety Disorders". https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/anxiety-disorders (accessed 2026-09-02). Cites its epidemiological source to patients.
  • Mental Health America — "Anxiety". https://mhanational.org/conditions/anxiety/ (accessed 2026-09-02). Over 21% of US adults (42.5 million) annually.
  • Mental Health Foundation of New Zealand — "Anxiety Support". https://mentalhealth.org.nz/conditions/condition/anxiety (accessed 2026-09-02). Explicitly explains how a doctor determines GAD.
  • Rethink Mental Illness — "What is anxiety?". https://www.rethink.org/advice-and-information/about-mental-illness/learn-more-about-conditions/anxiety-disorders/ (accessed 2026-09-02).
  • Mental Health Foundation (UK) — "Anxiety". https://www.mentalhealth.org.uk/explore-mental-health/a-z-topics/anxiety (accessed 2026-09-02).
  • SADAG — "South African Depression and Anxiety Group". https://www.sadag.org/ (accessed 2026-09-02). Has a dedicated GAD section and referral guides.
  • Deutsche Angst-Hilfe e.V. https://www.angstselbsthilfe.de/ (accessed 2026-09-02). Three audiences: people with anxiety disorders, self-help group facilitators, relatives.
  • Angst & Stressforeningen (Denmark). https://www.angstforeningen.dk/ (accessed 2026-09-02).
  • Vandrevala Foundation (India). https://www.vandrevalafoundation.com/ (accessed 2026-09-02).
  • Anxiety Canada — closure notice. https://www.anxietycanada.com/ (accessed 2026-09-02). Records the organisation's cessation of operations.

Coverage limits — read this before using the themes

  1. GAD-specific qualitative work exists but remains sparse. The audit search located studies of values/preferences, primary-care implementation, perinatal behaviours, motivational-interviewing experience and dietary-trial participation (PMIDs: 31908140, 33218311, 35716017, 21644188, 41587136). Several concern a treatment process or life stage rather than an unrestricted community sample, so generalisability remains limited.
  2. Geographic skew. Sources come predominantly from the UK, Canada, Australia, Spain and the US, with single studies from Pakistan. The countries with the largest treatment gaps — India (75.7%), Bangladesh (96.1% not seeking help) — contribute almost nothing to the lived-experience literature (Jayasankar 2023, PMID 38298878; Sarkar 2025, PMID 41061374).
  3. Sample sizes are small by design. 10 to 58 participants per qualitative study; these are depth studies, not prevalence estimates, and no percentage in this layer should be read as generalisable.
  4. Selection into qualitative research. Participants are people who already reached services, recognised their symptoms as emotional, and agreed to be interviewed. The theme most likely to be under-represented is that of people who never present at all — a group that, given the treatment gap, is the majority.
  5. Organisation pages are self-descriptions. They record what an organisation says it offers, not what it delivers, and none of them was independently evaluated here.
  6. Bot protection creates a systematic blind spot. Three of the largest anglophone organisations (ADAA, Mind, NAMI) could not be retrieved automatically, so their current content is entirely absent from this synthesis.
  7. No video or news-feature material was catalogued in this build. A future sweep should add verified patient-facing video and long-form journalism, observing the same ethics rules.
  8. Nothing here is a substitute for asking patients. No priority-setting partnership specific to GAD was located; the closest is a James Lind Alliance exercise on stopping psychiatric medication generally (Boland 2025, PMID 40790920).

Last curated: 2026-09-02.